Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Blood Neoplasia · 2026 · PMC13091438 · PMID 42007248

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The numeric lower viability of the azacitidine/venetoclax/cobicistat combination did not reach statistical significance ( Figure 6 A).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.